Invesco Biotechnology & Genome ETF
PBE
PBE
103 hedge funds and large institutions have $77.6M invested in Invesco Biotechnology & Genome ETF in 2022 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 14 increasing their positions, 28 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
50% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 28
Holders
103
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$1.77M | |
| 2 | +$1.64M | |
| 3 | +$1.08M | |
| 4 |
Goldman Sachs
New York
|
+$471K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$349K |
Top Sellers
| 1 | -$396K | |
| 2 | -$258K | |
| 3 | -$150K | |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$136K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$104K |